Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Bromopride
Accession Number
DB09018
Type
Small Molecule
Groups
Investigational
Description

Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

Structure
Thumb
Synonyms
  • 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
  • Bromoprid
  • Bromoprida
  • Bromopride
  • Bromopridum
External IDs
VAL 13081
International/Other Brands
Bromopan (UCI) / Digesan (Sanofi) / Emepride / Emoril / Movipride (Merck) / Plamet / Viadil
Categories
UNII
75473V2YZK
CAS number
4093-35-0
Weight
Average: 344.247
Monoisotopic: 343.08953961
Chemical Formula
C14H22BrN3O2
InChI Key
GIYAQDDTCWHPPL-UHFFFAOYSA-N
InChI
InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
IUPAC Name
4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
SMILES
CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC

Pharmacology

Indication

Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ADopamine D2 receptor
antagonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

40%.

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance

Renal, 10-14% as original compound.

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Bromopride.
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Bromopride.
BenzatropineThe risk or severity of adverse effects can be increased when Bromopride is combined with Benzatropine.
BrexpiprazoleThe therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Bromopride.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bromopride.
CabergolineThe therapeutic efficacy of Cabergoline can be decreased when used in combination with Bromopride.
DeutetrabenazineThe risk or severity of adverse effects can be increased when Bromopride is combined with Deutetrabenazine.
DihydrexidineThe therapeutic efficacy of Dihydrexidine can be decreased when used in combination with Bromopride.
DihydroergocornineThe therapeutic efficacy of Dihydroergocornine can be decreased when used in combination with Bromopride.
DihydroergocryptineThe therapeutic efficacy of Dihydroergocryptine can be decreased when used in combination with Bromopride.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patents 3,177,252; 3,219,528; and 3,357,978.

General References
Not Available
External Links
KEGG Drug
D07101
PubChem Compound
2446
PubChem Substance
310264975
ChemSpider
2352
ChEBI
95304
ChEMBL
CHEMBL399510
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromopride
ATC Codes
A03FA04 — Bromopride
MSDS
Download (105 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentDyspepsia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3177252No1962-07-171982-07-17Us
US3219528No1962-07-171982-07-17Us
US3357978No1964-02-281984-02-28Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)134-135U.S. Patents 3,177,252; 3,219,528; and 3,357,978.
Predicted Properties
PropertyValueSource
Water Solubility0.241 mg/mLALOGPS
logP2.36ALOGPS
logP1.56ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.58ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.34 m3·mol-1ChemAxon
Polarizability33.92 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00b9-2490000000-42a1d3cd086a6021ec5b

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Aminophenyl ethers
Direct Parent
Aminophenyl ethers
Alternative Parents
Methoxyanilines / Phenoxy compounds / Methoxybenzenes / Anisoles / 2-bromoanilines / Bromobenzenes / Alkyl aryl ethers / Aryl bromides / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds
show 5 more
Substituents
Aminophenyl ether / Methoxyaniline / Anisole / Phenoxy compound / 2-bromoaniline / Aniline or substituted anilines / Methoxybenzene / Alkyl aryl ether / Bromobenzene / Halobenzene
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F: Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004 Feb 15;19(4):379-90. [PubMed:14871277]

Drug created on June 23, 2014 15:53 / Updated on January 17, 2020 00:42